Gheorghe Doros, PhDAssociate Professor, Biostatistics
BiographyGheorghe Doros is Associate Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company’s Drug Discovery and Toxicology department. Professor Doros’s interests focus on Clinical Trials, Bayesian Statistics, asymptotic statistics, testing, and computational statistics. He is involved in projects that evaluate the effects of physical and emotional stresses of caregiving on physical and psychological health. He also serves as a statistical consultant to Boston Medical Center’s Amyloid Center and as biostatistician for the Boston University Clinical Research Training (CREST) project. At BUSPH, he teaches the course in Computational Statistics and Generalized Linear Models.
- Boston Medical Center
- Yale University, PhD
- Yale University, MA
- University of Bucharest , MS
- University of Bucharest , BS
- Published on 6/2/2014
Kaufman LB, Setiono TK, Doros G, Andersen S, Silliman RA, Friedman PK, Perls TT. An oral health study of centenarians and children of centenarians. J Am Geriatr Soc. 2014 Jun; 62(6):1168-73.
- Published on 4/8/2014
Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014 Jun; 11(6):1567-76.
- Published on 3/11/2014
Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014; 2014:683515.
- Published on 2/13/2014
Haider A, Meergans U, Traish A, Saad F, Doros G, Lips P, Gooren L. Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. Int J Endocrinol. 2014; 2014:496948.
- Published on 2/7/2014
Rosas HD, Doros G, Gevorkian S, Malarick K, Reuter M, Coutu JP, Triggs TD, Wilkens PJ, Matson W, Salat DH, Hersch SM. PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014 Mar 11; 82(10):850-7.
- Published on 1/31/2014
Vardi M, Novack V, Pencina MJ, Doros G, Burke DA, Elmariah S, Cutlip DE, Mauri L, Yeh RW. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014 May 1; 83(6):975-83.
- Published on 1/1/2014
Reid KF, Pasha E, Doros G, Clark DJ, Patten C, Phillips EM, Frontera WR, Fielding RA. Longitudinal decline of lower extremity muscle power in healthy and mobility-limited older adults: influence of muscle mass, strength, composition, neuromuscular activation and single fiber contractile properties. Eur J Appl Physiol. 2014 Jan; 114(1):29-39.
- Published on 12/9/2013
Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant. 2014 Mar; 49(3):434-9.
- Published on 11/23/2013
Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol. 2014 Feb 15; 113(4):691-6.
- Published on 10/15/2013
Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014 Mar; 68(3):314-29.
View 68 more publications:View full profile at BUMC